Cytokine Autoantibodies in Rheumatoid Arthritis

References

• Harris ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–89
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Petersen J, Halkjaer-Kristensen J, Ingemann-Hansen T. Interleukin-l-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis. Rheumatol Int 1985; 5: 79–82
   PubMed Web of Science ®Google Scholar
• Tiku K, Thakker-Varia S, Ramachandrula A, Tiku ML. Articular chondrocytes secrete IL-1, express membrane IL-1, and have IL-1 inhibitory activity. Cell Immunol 1992; 140: 1–20
   PubMedGoogle Scholar
• Hirota K, Akahoshi T, Endo H, Kondo H, Kashiwazaki S. Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor. Rheumatol Int 1992; 12: 13–6
   PubMed Web of Science ®Google Scholar
• Holt I, Cooper R G, Denton J, Meager A, Hopkins SJ. Cytokine inter-relationships and their association with disease activity in arthritis: see comments. Br J Rheumatol 1992; 31: 725–33
   PubMedGoogle Scholar
• Wood N C, Symons J A, Dickens E, Duff GW. In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Immunol 1992; 87: 183–9
   PubMed Web of Science ®Google Scholar
• Möller E, Valugerdi M A, Ridderstad A. Specific and non-specific autoreactive immunity. J Autoimmun 1992; 5: 37–44, Suppl A
   Google Scholar
• Deleuran B W, Chu C-Q, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: Implications for local actions of tumor necrosis factor a. Arthritis Rheum 1992; 35: 1170–78
   PubMed Web of Science ®Google Scholar
• Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y. Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992; 35: 1197–201
   PubMedGoogle Scholar
• Elliott M J, Maini R N, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681–90
   PubMed Web of Science ®Google Scholar
• Chen E, Keystone E C, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 1993; 36: 901–10
   PubMedGoogle Scholar
• Yanni G, Whelan A, Feighery C, Fitzgerald O, Bresnihan B. Morphometric analysis of synovial membrane blood vessels in rheumatoid arthritis: Associations with the immunohistologic features, synovial fluid cytokine levels and the clinical course. J Rheumatol 1993; 20: 634–8
   Google Scholar
• Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167–227
   PubMed Web of Science ®Google Scholar
• Lindsley H B, Smith D D, Cohick C B, Koch A E, Davis LS. Proinflammatory cytokines enhance human synoviocyte expression of functional intercellular adhesion molecule-1 (ICAM-1). Clin Immunol Immunopathol 1993; 68: 311–20
   PubMedGoogle Scholar
• Bendtzen K, Petersen J, Soeberg B. Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. II. Further studies of the monocyte - T cell interactions leading to lymphokine production. Acta Pathol Microbiol Immunol Scand [C] 1983; 91: 159–68
   Google Scholar
• Okamoto M, Sasano M, Goto M, et al. Suppressive effect of anti-rheumatic drugs on interleukin-1 beta release from human peripheral blood monocytes. Int J Immunopharmacol 1991; 13: 39–43
   Google Scholar
• Sipe J D, Bartle L M, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents teni-dap and naproxen: A possible correlate with clinical acute phase response. J Immunol 1992; 148: 480–4
   PubMed Web of Science ®Google Scholar
• Dank V A, Franic G M, Rathjen D A, Laurent R M, Brooks PM. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis 1992; 51: 946–50
   Google Scholar
• Amano Y, Lee S W, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-lα, interleukin-1β, and interleukin-6: Mediation by decreased mRNA stability. Mol Pharmacol 1993; 43: 176–82
   PubMed Web of Science ®Google Scholar
• Pronost S, Delecoeuillerie G, Rëdini F, et al. Interleukin-1 and naproxen down-regulate the expression of IL-1 receptors in cultured human rheumatoid synovial cells (HRSC). Agents Actions 1993; 213–7, Suppl 39
   Google Scholar
• Barrera P, Boerbooms A MT, Janssen E M, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070–9
   PubMed Web of Science ®Google Scholar
• Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259–62
   PubMed Web of Science ®Google Scholar
• Arend W P, Dayer J-M. Naturally occurring inhibitors of cytokines. Immuno-pharmacology of Joints and Connective Tissue, M E Davies, J T Dingle. Academic Press, New York 1994; 129–49
   Google Scholar
• Prümmer O, Seyfarth C, Scherbaum A, Drees N, Porzsolt F. Interferon-α antibodies in autoimmune diseases. J Interferon Res 1989; 9: S67–S74, Suppl 1
   PubMedGoogle Scholar
• Suzuki H, Akama T, Okane M, et al. Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum 1989; 32: 1528–38
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kamimura J, Ayabe T, Kashiwagi H. Demonstration of neutralizing autoantibodies against IL-lα in sera from patients with rheumatoid arthritis. J Immunol 1990; 145: 2140–6
   PubMedGoogle Scholar
• Suzuki H, Ayabe T, Kamimura J, Kashiwagi H. Anti-IL-lα autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin Exp Immunol 1991; 85: 407–12
   PubMed Web of Science ®Google Scholar
• Takemura H, Suzuki H, Yoshizaki K, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35: 940–3
   PubMedGoogle Scholar
• Svenson M, Poulsen L K, Fomsgaard A, Bendtzen K. IgG autoantibodies against interleukin la in sera of normal individuals. Scand J Immunol 1989; 29: 489–92
   PubMedGoogle Scholar
• Svenson M, Hansen M B, Bendtzen K. Distribution and characterization of autoantibodies to interleukin la in normal human sera. Scand J Immunol 1990; 32: 695–701
   Google Scholar
• Hansen M B, Svenson M, Diamant M, Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 1991; 33: 777–81
   PubMed Web of Science ®Google Scholar
• Hansen M B, Svenson M, Bendtzen K. Human anti-interleukin la antibodies. Immunol Lett 1991; 30: 133–40
   PubMed Web of Science ®Google Scholar
• Svenson M, Hansen M B, Kayser L, Rasmussen A K, Reimert C M, Bendtzen K. Effects of human anti-IL-lα autoantibodies on receptor binding and biological activities of IL-1. Cytokine 1992; 4: 125–33
   PubMedGoogle Scholar
• Sylvester I, Yoshimura T, Sticherling M, et al. Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. J Clin Invest 1992; 90: 471–81
   PubMed Web of Science ®Google Scholar
• Hansen M B, Svenson M, Diamant M, Bendtzen K. High-affiity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 1993; 5: 72–80
   PubMedGoogle Scholar
• Svenson M, Hansen M B, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92: 2533–9
   PubMed Web of Science ®Google Scholar
• Hansen M B, Svenson M, Bendtzen K. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-α in normal human sera. Clin Exp Immunol 1992; 88: 559–62
   Google Scholar
• Bendtzen K, Svenson M, Jønsson V, Hippe E. Autoantibodies to cytokines - friends or foes?. Immunol Today 1990; 11: 167–9
   PubMedGoogle Scholar
• Hansen M B, Svenson M, Abell K, et al. Sex- and age-dependency of IgG auto-antibodies against IL-lα in healthy humans. Eur J Clin Invest 1994; 24: 212–8
   PubMedGoogle Scholar
• Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Hansen M B, Ross C, Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Methods 1990; 127: 241–8
   PubMed Web of Science ®Google Scholar
• Grassi J, Roberge C J, Frobert Y, Pradelles P, Poubelle PE. Determination of IL1α, IL1β and IL2 in biological media using specific enzyme immunometric assays. Immunol Rev 1991; 119: 125–45
   PubMed Web of Science ®Google Scholar
• Leusch H-G, Sitzler G, Markos-Pusztai S. Failure to demonstrate TNFα-specific autoantibodies in human sera by ELISA and Western blot. J Immunol Methods 1991; 139: 145–7
   PubMed Web of Science ®Google Scholar
• Svenson M, Hansen M B, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1)β and IL-1 receptor antagonist (IL-Ira) to human serum. High-affinity binding of IL-lra to soluble IL-1 receptor type I. Cytokine 1993; 5: 427–35
   PubMed Web of Science ®Google Scholar
• Peichl P, Ceska M, Broell H, Effenberger F, Lindley I JD. Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 19–22
   PubMedGoogle Scholar
• Crabtree J E, Peichl P, Wyatt J I, Stachl U, Lindley I JD. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993; 37: 65–70
   PubMed Web of Science ®Google Scholar
• Reitamo S, Remitz A, Varga J, et al. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 1993; 129: 189–93
   PubMedGoogle Scholar
• Sylvester I, Suffredini A F, Boujoukos A J, et al. Neutrophil attractant protein-I and monocyte chemoattractant protein-1 in human serum. Effects of intravenous lipopolysaccharide on free attractants, specific IgG autoantibodies and immune complexes. J Immunol 1993; 151: 3292–8
   PubMedGoogle Scholar
• Arend W P, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15
   PubMed Web of Science ®Google Scholar
• Hovdenes J, Kvien T K, Hovdenes AB. IL-6 in synovial fluids, plasma and supernatants from cultured cells of patients with rheumatoid arthritis and other inflammatory arthritides. Scand J Rheumatol 1990; 19: 177–82
   PubMed Web of Science ®Google Scholar
• Eastgate J A, Symons J A, Wood N C, Capper S J, Duff GW. Plasma levels of interleukin-1-alpha in rheumatoid arthritis. Br J Rheumatol 1991; 30: 295–97
   PubMedGoogle Scholar
• Wood N C, Dickens E, Symons J A, Duff GW. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 1992; 62: 295–300
   PubMedGoogle Scholar
• Falus A, Lakatos T, Smolen J. Dissimilar biosynthesis of interleukin-6 by different areas of synovial membrane of patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1992; 21: 116–9
   PubMed Web of Science ®Google Scholar
• Yanni G, Whelan A, Feighery C, et al. Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration. Clin Exp Immunol 1993; 93: 387–95
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ichijo Y, Nagatake H, Watanabe N, Nishizawa K, Goto M. Processing of interleukin-1β in synovial cells freshly isolated from patients with rheumatoid arthritis. Biochem Biophys Res Commun 1994; 199: 1035–40
   PubMed Web of Science ®Google Scholar
• Suzuki H, Takemura H, Yoshizaki K, et al. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 1994; 152: 935–42
   PubMed Web of Science ®Google Scholar